NewAmsterdam Pharma Announces Positive Topline Data from …

Q: Does newamsterdam Pharma's cholesterol drug lower cardiovascular risk?

NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock catapulted.

Q: How much money did newamsterdam Pharma make in 2024?

Matter of fact, all co-primary endpoints were met from the phase 3 TANDEM study, using this fixed-dose combination of obicetrapib. Financials According to the 10-Q SEC Filing, NewAmsterdam Pharma had cash of $422.7 million as of September 30th of 2024.

Q: Should you buy newamsterdam pharma company (NAMS – research report)?

Serge Belanger, an analyst from Needham, maintained the Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report). The associated price target remains the same with $36.00. Serge Belanger has given his Buy rating due to a combination of factors including the promising outcomes from NewAmsterdam Pharma’s phase 3 TANDEM trial.

Q: Is newamsterdam Pharma a good stock to buy?

Overall, the Buy rating reflects optimism about NewAmsterdam Pharma’s future prospects, particularly with the expected data from larger trials that could mitigate current concerns. According to TipRanks, Belanger is a 3-star analyst with an average return of 1.6% and a 43.25% success rate.

Q: What risks should investors consider before investing in newamsterdam Pharma?

Risks To Business There are several risks that investors should be aware of before investing in NewAmsterdam Pharma. The first riskto consider would be in terms of the recently released results from the phase 3 BROADWAY study, along with the other trials like TANDEM.

Q: What is newamsterdam's Phase 3 clinical development program?

The Company’s global, pivotal Phase 3 clinical development program consists of four trials in over 12,250 patients. "2024 was a landmark year for NewAmsterdam, underscored by exceptional clinical and operational execution.

Dec 10, 2024 · NewAmsterdam Pharma N.V.-- Achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with …

CouponFollow Extension

3%
OFF

NewAmsterdam Pharma Announces Positive Topline Data From …

3 weeks from now

Jul 29, 2024 · The BROOKLYN trial met its primary endpoint, achieving an LS mean reduction of 36.3% (p < 0.0001) compared to placebo at day 84, which was sustained at day 365 with an …

yahoo.com

4%
OFF

Biotech Stock NewAmsterdam Pharma Skyrockets After …

3 weeks from now

Dec 10, 2024 · NewAmsterdam stock skyrocketed 41.4% to close at 26.19. Shares opened at their highest point since November 2022. The biotech stock broke out of a buy point at 25.32 …

investors.com

40%
OFF

NewAmsterdam Shares Sign Drug Improves Cardiovascular Outcomes

3 weeks from now

Dec 10, 2024 · NewAmsterdam’s stock fell in the aftermath of both readouts despite the trials hitting their primary endpoints. This time, the biotech’s stock climbed more than 40% to around …

fiercebiotech.com

FAQs about NewAmsterdam Pharma Announces Positive Topline Data from … Coupon?

Does newamsterdam Pharma's cholesterol drug lower cardiovascular risk?

NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock catapulted. ...

How much money did newamsterdam Pharma make in 2024?

Matter of fact, all co-primary endpoints were met from the phase 3 TANDEM study, using this fixed-dose combination of obicetrapib. Financials According to the 10-Q SEC Filing, NewAmsterdam Pharma had cash of $422.7 million as of September 30th of 2024. ...

Should you buy newamsterdam pharma company (NAMS – research report)?

Serge Belanger, an analyst from Needham, maintained the Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report). The associated price target remains the same with $36.00. Serge Belanger has given his Buy rating due to a combination of factors including the promising outcomes from NewAmsterdam Pharma’s phase 3 TANDEM trial. ...

Is newamsterdam Pharma a good stock to buy?

Overall, the Buy rating reflects optimism about NewAmsterdam Pharma’s future prospects, particularly with the expected data from larger trials that could mitigate current concerns. According to TipRanks, Belanger is a 3-star analyst with an average return of 1.6% and a 43.25% success rate. ...

What risks should investors consider before investing in newamsterdam Pharma?

Risks To Business There are several risks that investors should be aware of before investing in NewAmsterdam Pharma. The first riskto consider would be in terms of the recently released results from the phase 3 BROADWAY study, along with the other trials like TANDEM. ...

What is newamsterdam's Phase 3 clinical development program?

The Company’s global, pivotal Phase 3 clinical development program consists of four trials in over 12,250 patients. "2024 was a landmark year for NewAmsterdam, underscored by exceptional clinical and operational execution. ...